Company intelligence / Profile preview
TheVax Genetics Vaccine Co., Ltd.
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
Overview
The company’s lead candidate, TVGV‑1, is a therapeutic monovalent vaccine targeting high-grade HPV-induced cervical lesions. It has completed at least a Phase 2a double-blind randomized study assessing safety and efficacy in women with histologically confirmed high-grade squamous intraepithelial lesions (HSIL). Other candidates include multivalent vaccines for cervical cancer/precancerous lesions and a therapeutic vaccine for hepatitis B. Published preclinical data show that their HBx-based vaccine can accelerate viral antigen clearance in animal models of chronic hepatitis B.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Therapeutic vaccines
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on TheVax Genetics Vaccine Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TheVax Genetics Vaccine Co., Ltd..